Chronic pain
Drug research and approvals for chronic pain: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 905 studies of chronic pain are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, FDA has 2 approved and 0 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 905
- Trials authorized in Canada: 0
- FDA orphan approvals: 2
- EU medicines: 1
- Thoracic Mobilization Versus Thoracic Strengthening for Chronic Mechanical Neck PainNCT07949565 · Not applicable · Ibadat International University, Islamabad · starts Jul 5, 2026
- Efficacy of Automated Tuina and Acupuncture for Treating Chronic Lower Back PainNCT07945197 · Not applicable · Nanyang Technological University · starts Jan 1, 2025
- Effects of Cervicothoracic Junction Manipulation Among Chronic Neck PainNCT07945847 · Not applicable · Riphah International University · starts Nov 10, 2026
- Cardiopulmonary Exercise Active Health Cohort StudyNCT07935187 · Not reported · Peking University Third Hospital · starts May 11, 2026
- Tracking Outcomes in Patients With Chronic Pain Prescribed Intravenous LidocaineNCT07929636 · Not reported · International Spine, Pain and Performance Center · starts Nov 6, 2023
- Ultrasound-Guided Thoracolumbar Fascia Injection for Chronic Low Back Pain in Patients With Type 2 DiabetesNCT07927530 · Not applicable · Hatice Zehra FERHATLAR · starts Oct 23, 2026
- Cognitive Rehabilitation of Executive Dysfunction With the Goal Management Training (GMT) - Exploring Variations in…NCT07924774 · Not applicable · Karolinska Institutet · starts Mar 1, 2022
- Phenotype-based Model for Managing Chronic Post-treatment Pain Among Head and Neck Cancer Survivors: a Pilot StudyNCT07919457 · Phase 2 · Shaukat Khanum Memorial Cancer Hospital & Research Centre · starts Jul 16, 2026
- Rewiring the Chronic Pain Experience: Single-Session Model of Pain Reprocessing Therapy (PRT) at The Ottawa HospitalNCT07919626 · Not applicable · Ottawa Hospital Research Institute · starts Oct 16, 2026
Approved 9
- FentanylMu opioid receptor agonist
- OxycodoneMu opioid receptor agonist
- BuprenorphineMu opioid receptor agonist
- TramadolMu opioid receptor agonist
- MorphineMu opioid receptor agonist
- TapentadolMu opioid receptor agonist
- Alcohol
- DuloxetineSerotonin transporter inhibitor
- LubiprostoneChloride channel protein 2 opener
Phase 3 12 of 20
- LidocaineSodium channel alpha subunit blocker
- KetamineGlutamate [NMDA] receptor negative allosteric modulator
- PregabalinVoltage-gated calcium channel modulator
- OxymorphoneOpioid receptors; mu/kappa/delta agonist
- GabapentinVoltage-gated calcium channel modulator
- AcetaminophenCyclooxygenase inhibitor
- BupivacaineSodium channel protein type IV alpha subunit blocker
- HydrocodoneOpioid receptors; mu/kappa/delta agonist
- HydromorphoneMu opioid receptor agonist
- Cannabinol
- IbuprofenCyclooxygenase inhibitor
- MethadoneMu opioid receptor agonist
Phase 2 12 of 17
- CannabidiolCannabinoid CB1 receptor negative allosteric modulator
- OxytocinOxytocin receptor agonist
- DronabinolCannabinoid CB1 receptor agonist
- OnabotulinumtoxinaSynaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- DiclofenacCyclooxygenase inhibitor
- MethylphenidateDopamine transporter inhibitor
- MexiletineSodium channel alpha subunit blocker
- QuinineFerriprotoporphyrin IX inhibitor
- SufentanilMu opioid receptor agonist
- AcetazolamideCarbonic anhydrase I inhibitor
- MetamizoleCyclooxygenase inhibitor
- CarbidopaDOPA decarboxylase inhibitor
Phase 1 or earlier 12 of 20
- AZD1386Vanilloid receptor antagonist
- PF-04531083Sodium channel protein type X alpha subunit blocker
- KetorolacCyclooxygenase inhibitor
- MidazolamGABA-A receptor; anion channel positive allosteric modulator
- SimvastatinHMG-CoA reductase inhibitor
- OmeprazolePotassium-transporting ATPase inhibitor
- DexmedetomidineAdrenergic receptor alpha-2 agonist
- CaffeineAdenosine receptor antagonist
- TolbutamideSulfonylurea receptor 1, Kir6.2 blocker
- PrilocaineSodium channel alpha subunit blocker
- EpinephrineAdrenergic receptor agonist
- FaxeladolMu opioid receptor agonist
How its trials ended
2,485 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 398 whose ending is known, 44% met their primary endpoint, 6% missed it and 50% stopped early.
- Completed, result not reported1,13546%
- Ongoing63826%
- Status unknown31413%
- Met its primary endpoint1757%
- Stopped: other or unclear1175%
- Stopped: enrollment or feasibility492%
- Missed its primary endpoint231%
- Stopped: sponsor or business decision141%
- Stopped: funding12<1%
- Stopped: lack of efficacy6<1%
- Stopped: safety2<1%
| Mar 19, 1999 | Lidoderm PatchFor relief of allodynia (painful hypersensitivity), and chronic pain in postherpetic neuralgia. | Teikoku Pharma USA, Inc. | Approved |
| Jul 19, 1991 | InfumorphFor intrathecal or epidural infusion in the treatment of tractable chronic pain. It was developed for use in continuous microinfusion… | Elkins-Sinn, Inc. | Approved |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Feb 21, 2005 | PrialtZiconotide | Esteve Pharmaceuticals GmbH | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA